


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on February 17, 2006.


Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1646
Patent Application
Docket No. ARS-103
Serial No. 10/510,014

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Bruce D. Hissong, Ph.D.
Art Unit : 1646
Applicants : Amanda Proudfoot, Maria Kosco-Vilbois, Timothy Wells
Serial No. : 10/510,014
Filed : September 30, 2004
Conf. No. : 4504
For : Chemokines Mutants Having Improved Oral Bioavailability

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicants have not submitted a copy of the U.S. patent cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

02/22/2006 SHASSEN1 00000056 190065 10510014

02 FC:1806 180.00 DA

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/gyl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/510,014
				Filing Date	September 30, 2004
				First Named Inventor	Amanda Proudfoot
				Art Unit	1646
				Examiner Name	Bruce D. Hissong, Ph.D.
Sheet	1	of	2	Attorney Docket Number	ARS-103


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US- 5,854,412	12-29-1998	Rollins <i>et al.</i>	All
	U2				
	U3				
	U4				
	U5				
	U6				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 98/06751	02-19-1998	Research Corporation Technologies, Inc.	All	
	F2	WO 99/33989	07-08-1999	Fondazione Centro San Raffaele Del Monte Tabor	All	
	F3	WO 00/44408	08-03-2000	Leukosite, Inc.	All	
	F4					
	F5					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Patent Work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/510,014
Filing Date	September 30, 2004
First Named Inventor	Amanda Proudfoot
Group Art Unit	1646
Examiner Name	Bruce D. Hissong, Ph.D.
Attorney Docket Number	ARS-103

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	APPAY, V. <i>et al.</i> "Aggregation of RANTES is Responsible for Its Inflammatory Properties", <i>The Journal of Biological Chemistry</i> , September 24, 1999, pp. 27505-27512, Vol. 274, No. 39.	
	R2	CZAPLEWSKI, L. <i>et al.</i> "Identification of Amino Acid Residues Critical for Aggregation of Human CC Chemokines Macrophage Inflammatory Protein (MIP)-1 α , MIP-1 β , and RANTES", <i>The Journal of Biological Chemistry</i> , June 4, 1999, pp. 16077-16084, Vol. 274, No. 23.	
	R3	FRITCHLEY, S.J. <i>et al.</i> "Identification of Heparan Sulphate Binding Site In Rantes: Consequences For Leukocyte Activation", <i>Immunology</i> , December 1999, p. 47, (Joint Congress of the British Society for Immunology and the British Society for Allergy & Clinical Immunology, Harrogate, England, UK); Vol. 98, No. Suppl. 1, XP-001010396.	
	R4	GRAHAM, G. <i>et al.</i> "Uncoupling of stem cell inhibition from monocyte chemoattraction in the MIP-1 α by mutagenesis of the proteoglycan binding site", <i>The EMBO Journal</i> , 1996, pp. 6506-6515, (Oxford University Press); Vol. 15, No. 23, XP-002173221.	
	R5	HOOGEWERF, A. <i>et al.</i> "Glycosaminoglycans Mediate Cell Surface Oligomerization of Chemokines", <i>Biochemistry</i> , 1997, pp. 13570-13578, Vol. 36.	
	R6	KOOPMANN, W. <i>et al.</i> "Identification of a Glycosaminoglycan-binding Site in Chemokine Macrophage Inflammatory Protein-1 α ", <i>The Journal of Biological Chemistry</i> , April 11, 1997, pp. 10103-10109, Vol. 272, No. 15, XP-002171678.	
	R7	KUSCHERT, G. <i>et al.</i> "Glycosaminoglycans Interact Selectively with Chemokines and Modulate Receptor Binding and Cellular Responses", <i>Biochemistry</i> , 1999, pp. 12959-12968, Vol. 38.	
	R8	LAURENCE, J. <i>et al.</i> "Importance of Basic Residues and Quarternary Structure in the Function of MIP-1 β : CCR5 Binding and Cell Surface Sugar Interactions", <i>Biochemistry</i> , April 24, 2001, pp. 4990-4999, Vol. 40, No. 16, XP-002193384.	
	R9	PROUDFOOT, A. "Probing the role of the GAC/Chemokine interaction", CHEMOKINE GORDON CONFERENCE (Session I, July 24, 2000).	
	R10	PROUDFOOT, A. <i>et al.</i> "THE BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity", <i>The Journal of Biological Chemistry</i> , April 6, 2001, pp. 10620-10626, Vol. 276, No. 14.	
	R11	SCHWARTZ, M. and WELLS, T.N.C. "Interfering with Chemokine networks--the hope for new therapeutics", <i>Current Opinion in Chemical Biology</i> , 1999, pp. 407-417, Vol. 3.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.